Impact of trimethoprim-sulfemethoxazole prophylaxis on falciparum malaria infection and disease

Journal of Infectious Diseases

Volumn 192, Issue 10, 2005, Pages 1823-1829

  Thera, Mahamadou A ^a   Sehdev, Paul S ^b   Coulibaly, Drissa ^a   Traore, Karim ^a   Garba, Mamane N ^a   Cissoko, Yacouba ^a   Kone, Abdoulaye ^a   Guindo, Ando ^a   Dicko, Alassane ^a   Besvogui, Abdoul H ^a   Djimde, Abdoulaye A ^a   Lyke, Kirsten E ^b   Diallo, Dapa A ^a   Doumbo, Ogobara K ^a   Plowe, Christopher V ^b,c  

^a UNIVERSITY OF BAMAKO   (Mali)

^b University of Maryland School of Medicine Center for Vaccine Development   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; COTRIMOXAZOLE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; FOLIC ACID ANTAGONIST;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MUTATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; ADOLESCENT; ANIMAL; CHEMOPROPHYLAXIS; CHILD; DRUG EFFECT; DRUG RESISTANCE; GENETICS; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANIMALS; ANTIMALARIALS; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; FOLIC ACID ANTAGONISTS; HUMANS; MALARIA, FALCIPARUM; MALE; MUTATION; PLASMODIUM FALCIPARUM; PREVALENCE; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 27744526779     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/498249     Document Type: Article

References (31)

1. UNAIDS. AIDS epidemic update, December 2004. Available at: http: //www.unaids.org/wad2004/report.html. Accessed 6 October 2005.
2. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999; 353:1469-75.
3. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353:1463-8.
4. UNAIDS. Provisional WHO/UNAIDS secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. Available at: http://www.unaids.org/html/pub/ publications/irc-pub04/ recommendation_en_pdf.htm. Accessed 6 October 2005.
5. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428-34.
6. Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004; 364:1865-71.
7. Petersen E. In vitro susceptibility of Plasmodium falciparum malaria to pyrimethamine, sulfadoxine, trimethoprim and sulfamethoxazole, singly and in combination. Trans R Soc Trop Med Hyg 1987; 81:238-41.
8. Wang P, Read M, Sims PF, Hyde JE. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol Microbiol 1997; 23:979-86.
9. Triglia T, Menting JGT, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 1997; 94: 13944-9.
10. Martin DC, Arnold JD. Trimethoprim in therapy of acute attacks of malaria. J Clin Pharmacol J New Drugs 1967; 7:336-41.
11. Feikin DR, Dowell SF, Nwanyanwu OC, et al. Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. J Infect Dis 2000; 181:1501-5.
12. Iyer JK, Milhous WK, Cortese JF, Kublin JG, Plowe CV. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 2001; 358:1066-7.
13. Doumbo OK, Kayentao K, Djimde A, et al. Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis. J Infect Dis 2000; 182:993-6.
14. Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxine- pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet 1999; 353:632-6.
15. Schellenberg D, Menendez C, Kahigwa E, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 2001; 357:1471-7.
16. Coulibaly D, Diallo DA, Thera MA, et al. Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop Med Hyg 2002; 67:604-10.
17. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria (WHO/HTM/RBM/2003.50). Geneva: World Health Organization, 2003.
18. Kilian AH, Jelinek T, Prislin I, et al. Resistance in vivo of Plasmodium falciparum to co-trimoxazole in western Uganda. Trans R Soc Trop Med Hyg 1998; 92:197-200.
19. World Health Organization, Communicable Diseases Cluster. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000;94(Suppl 1):S1-90.
20. Plowe CV, Doumbo OK, Djimde A, et al. Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacy. Am J Trop Med Hyg 2001; 64:242-6.
21. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 1993; 87:75-8.
22. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 1995; 52:565-8.
23. Diourte Y, Djimde A, Doumbo OK, et al. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. Am J Trop Med Hyg 1999; 60:475-8.
24. Plowe CV, Kublin JG, Dzinjalamala FK, et al. Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. BMJ 2004; 328:545.
25. Gasasira AF, Dorsey G, Nzarubara B, et al. Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg 2003; 68:127-32.
26. Clyde DF, Shute GT. Resistance of Plasmodium falciparum in Tanganyika to pyrimethamine administered at weekly intervals. Trans R Soc Trop Med Hyg 1957; 51:505-13.
27. Roper C, Pearce R, Bredenkamp B, et al. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 2003; 361:1174-81.
28. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004; 305: 1124.
29. Asrat D, Amanuel YW. Prevalence and antibiotic susceptibility pattern of bacterial isolates from blood culture in Tikur Anbassa Hospital, Addis Ababa, Ethiopia. Ethiop Med J 2001; 39:97-104.
30. Mutabingwa TK. Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy! Acta Trop 2005; 95:305-15.
31. White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999; 353:1965-7.